Powered by
FLINT—XlerateHealth, a national healthcare startup accelerator based in Louisville, Ky., announced the selection of six startup companies to its second annual cohort in Flint. The companies will participate in a …
EAST LANSING—The Michigan State University Foundation’s Conquer Accelerator announced the launch of its fifth season and summer 2020 cohort. The 10-week accelerator welcomes five selected teams to its East Lansing …
FERNDALE—Bollinger Motors announced it had been granted United States Patent No. US20190351950A1 on two uniquely named features of its electric truck—called “Passthrough” and “Frunkgate.” Both features harness the opportunity, presented …
ANN ARBOR—The Michigan “angel investor” community released its 2019 annual research report, showing an increase in the number of angel investors and the amount they invested in Michigan startups last …
FERNDALE—Bollinger Motors, the electric truck developer, Thursday announced plans to manufacture and sell an all-electric chassis cab truck called the B2 Chassis Cab. The company says the truck is the …
ANN ARBOR—The Michigan Growth Capital Symposium, the Midwest’s oldest and largest event for young companies seeking capital, will be held online Tuesday, May 5 as the Midwest Venture Showcase 2020. …
ANN ARBOR—BlueWillow Biologics, the Ann Arbor-based clinical-stage biopharmaceutical company developing novel anti-infective products and nasal vaccines, announced the appointment of Chad Costley, MD, as chief medical officer. Costley is a …
ANN ARBOR—Millendo Therapeutics Inc., a biopharmaceutical company primarily focused on developing novel treatments for endocrine diseases, announced today that it is discontinuing the development of livoletide as a potential treatment …
ANN ARBOR—Millendo Therapeutics Inc. (Nasdaq: MLND), a pharmaceutical startup focused on developing novel treatments for orphan endocrine diseases, provided a corporate update and reported financial results for the year ended …
ANN ARBOR—Esperion Therapeutics Inc. (Nasdaq: ESPR) announced U.S. Food and Drug Administration approval of Nexlizet, a combination tablet of Esperion’s new non-statin cholesterol reducing drug bempedoic acid and an earlier …